Double-Blind Study of Topical WBI-1001 Cream on Patients With Psoriasis

Psoriasis Clinical Trial

— WBI-1001-101  

Official title:

A Randomized, Double-Blind Phase I Study to Evaluate Topically Applied WBI-1001 Cream in Patients With Psoriasis.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00830817
• Other study ID #: WBI-1001-101; control # 114963
• Status: Completed
• Phase: N/A
• First received: January 26, 2009
• Last updated: January 27, 2009
• Start date: July 2007
• Est. completion date: June 2008

Study information

• Verified date: January 2009
• Source: Welichem Biotech Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate primarily the safety and tolerability and secondarily the efficacy of topically applied WBI-1001 cream in patients with mild to moderate psoriasis. Double-blind, randomized, placebo controlled study of 36 patients, treated for 28 days plus a 7 day follow-up.in which the patients were divided into six cohorts: Cohort 1 at 0.5% QD;Cohort 2 at 0.5% BID; Cohort 3 at 1.0% QD; Cohort 4 at 1.0% BID; Cohort 5 at 2.0% QD; Cohort 6 at 2.0% BID.Efficacy assessed by PGA,target lesion assessment and BSA. Safety assessed through vital signs, ECG, AEs and Plasma PK via Cmin, Cmax,Tmax and AUCo-t.

Description:

Patients initiated screening within 4 weeks of commencing study treatment. Based on progression of the study, at day 0 patients were assigned to one of six treatment Cohorts. Patients were randomized to treat all areas except the face, scalp, groin and genital areas. Patients in Cohort 1 were treated on one side with a thin layer of active cream and the other with placebo; in the absence of significant AEs by 14 days after the last treatment in the Cohort escalation to the next Cohort was allowed, and each Cohort respectively.

During the treatment period patients visited the study centre weekly for safety, tolerability and efficacy assessment. On these study visit days blood draws were done between 7.00 and 10.00am prior to that morning's application of cream.

The study enrolled healthy male and female patients aged 18-65 y.o. with clinical diagnosis of stable plaque psoriasis for >months affecting a maximum of 6% of BSA with a minimum of 0.5% BSA on each side of the body and a minimum of one plaque at least 2x2 cm on each side excluding elbow and knee.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: June 2008
• Est. primary completion date: April 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• PGA score at day 0 must be 2,3 or 4.

• In good overall health.

• Women of child bearing potential to have negative serum beta-human chorionic gonadotropin pregnancy test before randomization

• Must be prepared to use adequate means of contraception

• Must not be lactating.

• Male partners of females in the study must be prepared to use adequate means of contraception.

• Must comply with study protocol and attend all visits.

• Provide written consent prior to participating in the study.

Exclusion Criteria:

• Spontaneously improving or rapidly deteriorating psoriasis.

• Patients with other diseases (especially dermatological, immunodeficiency or neurological/psychiatric) that might interfere with assessment of plaque psoriasis.

• Systemic immunomodulatory therapy in past 36 weeks, phototherapy in past 4 weeks, various psoriatic chemotherapies and beta blockers in the past 2 weeks

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Psoriasis

Locations

Country	Name	City	State
Canada	Innovaderm Research inc.	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Welichem Biotech Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate safety and tolerability of topically applied WBI-1001 cream, and to assess the pharmacokinetics based on plasma concentrations		35 days	Yes
Secondary	Obtain initial evaluation of efficacy of topically applied WBI-1001 cream in patients with mild to moderate psoriasis.		35 days	No